ΔNp73α regulates MDR1 expression by inhibiting p53 function

Oncogene

Volumn 27, Issue 15, 2008, Pages 2170-2176

  Vilgelm, A ^a,b   Wei, J X ^a   Piazuelo, M B ^a   Washington, M K ^a   Prassolov, V ^b   El Rifai, W ^a,c   Zaika, A ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Gastric tumor; p53; p73

Indexed keywords

GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; PROTEIN P73; ABCB1 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP73 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; PROTEIN VARIANT; STOMACH CARCINOMA; UPREGULATION; CARCINOMA; CELL CULTURE; COMPARATIVE STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

CARCINOMA; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; NUCLEAR PROTEINS; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 41649120554     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210862     Document Type: Article

References (30)

1. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G et al. (2002). Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251.
2. Chin KV, Ueda K, Pastan I, Gottesman MM. (1992). Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462.
3. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim B et al. (2002). Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 86: 1578-1585.
4. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. (2005). Clinical relevance of dominantnegative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372-8383.
5. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al. (1993). Gain of function mutations in p53. Nat Genet 4: 42-46.
6. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L et al. (2006). DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24: 805-815.
7. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E et al. (2001). Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522.
8. Guan M, Chen Y. (2005). Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol 58: 1175-1179.
9. Hoppe-Seyler F, Butz K. (1993). Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 67: 3111-3117.
10. Hotta T, Tanimura H, Iwahashi M, Tani M, Tsunoda T, Noguchi K et al. (1999). P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer. Surg Today 29: 591-596.
11. Hu Z, Jin S, Scotto KW. (2000). Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 275: 2979-2985.
12. Johnson RA, Ince TA, Scotto KW. (2001). Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276: 27716-27720.
13. Johnson RA, Shepard EM, Scotto KW. (2005). Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 280: 13213-13219.
14. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819.
15. Lacueva FJ, Teruel A, Calpena R, Medrano J, Mayol MJ, Perez-Vazquez MT et al. (1998). Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology 32: 328-334.
16. Liu G, Nozell S, Xiao H, Chen X. (2004). DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 24: 487-501.
17. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H et al. (2002). Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 22: 2575-2585.
18. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
19. Petrenko O, Zaika A, Moll UM. (2003). deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23: 5540-5555.
20. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. (2000). An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
21. Stiewe T, Putzer BM. (2002). Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9: 237-245.
22. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. (1997). p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94: 11037-11042.
23. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. (2004). p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 64: 6390-6393.
24. Tomkova K, El-Rifai W, Vilgelm A, Kelly MC, Wang TC, Zaika AI. (2006). The gastrin gene promoter is regulated by p73 isoforms in tumor cells. Oncogene 25: 6032-6036.
25. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M et al. (2004). Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911.
26. Vollrath V, Chianale J, Gonzalez S, Duarte I, Andrade L, Ibanez L. (1991). Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions. Virchows Arch B Cell Pathol Incl Mol Pathol 60: 133-138.
27. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M et al. (2002). DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21: 3796-3803.
28. Vousden KH. (2006). Outcomes of p53 activation - spoilt for choice. J Cell Sci 119: 5015-5020.
29. Wallner J, Depisch D, Gsur A, Gotzl M, Haider K, Pirker R. (1993). MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 71: 667-671.
30. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M et al. (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780.